Positive and Negative Syndrome Scale (PANSS)

Abstract

The Positive and Negative Syndrome Scale (PANSS) is a standardized clinical rating instrument designed to assess the severity of psychopathology in individuals diagnosed with schizophrenia. Developed on the fundamental premise that schizophrenia comprises distinct symptom dimensions—positive syndrome (productive symptoms) and negative syndrome (deficit features)—the PANSS provides a quantitative measure used primarily for monitoring treatment response.

The scale is widely employed at critical junctures in patient care, such as upon inpatient admission and at the initiation or adjustment of medication, serving to gauge the effect of therapeutic interventions over time. Despite limitations concerning its length and capacity to fully measure cognitive functioning, the PANSS is recognized as a competent, stand-alone clinical screening tool for psychosis due to its robust clinical predicting power and utility in outcome assessment.

Keywords

PANSS, schizophrenia, rating scale, positive symptoms, negative symptoms, psychopathology, clinical assessment, psychometrics, MHS.

Authors

Stanley R. Kay, Lewis A. Opler, Abraham Fiszbein.

Purpose

The primary purpose of the PANSS is to provide a detailed, quantitative measure of symptom severity in patients with schizophrenia. This objective measurement is crucial for longitudinal tracking of patient illness severity and for evaluating the efficacy of pharmacological and psychosocial treatment protocols.

This clinical tool is strategically employed at various stages of treatment to provide standardized assessment points: 1) upon an inpatient’s admission to establish baseline severity; 2) at the outset of taking a new medication to determine initial response; and 3) weeks or months into treatment to accurately gauge the effect of the intervention (Opler et al., 2006). The use of the PANSS helps clinicians target and gauge therapy, thereby predicting outcomes in clinical practice.

Construct

The PANSS is structured to measure three core, hypothesized dimensions of schizophrenic symptomatology: the positive syndrome, the negative syndrome, and general psychopathology. The scale’s design is rooted in the concept that these symptom clusters represent fundamental, measurable features of the disorder.

The scale items are categorized into three subscales, each focusing on a distinct clinical domain: The Positive Syndrome subscale addresses productive symptoms such as delusions, conceptual disorganization, and hallucinatory behavior. The Negative Syndrome subscale measures deficit features, including emotional withdrawal, poor rapport, and blunted affect. Finally, the General Psychopathology subscale covers a broader range of symptoms that do not fit neatly into the positive or negative categories, such as anxiety, depression, and somatic concerns.

Validity

Early validation efforts, specifically studies conducted in 1994 involving patients diagnosed with DSM-III-R schizophrenia, established that the construct validity of the PANSS was adequate. Furthermore, criterion validity was high when the positive and negative subscales were compared to established measures like the Scales for the Assessment of Positive Symptoms (SAPS) and the Scales for the Assessment of Negative Symptoms (SANS).

However, these initial evaluations highlighted certain psychometric weaknesses. Specifically, the internal consistency of the scale as a whole was sometimes found to be insufficient. Critically, the factorial validity of the positive scale was noted as poor, suggesting that the scale might have oversimplified the complex relationship between positive and negative symptoms or that the items did not load onto the intended theoretical factors cleanly. Despite these early complications, the scale scores were generally found to be normally distributed (Cuesta & Peralta, 1994; Opler, 1987).

Reliability

Contemporary research has confirmed strong reliability for the PANSS, solidifying its psychometric properties, particularly across its subscales. Internal consistencies (Cronbach’s alpha) are reported as adequate to good:

• The Positive Subscale demonstrated adequate internal consistency (α = 0.73).
• The Negative Subscale showed good internal consistency (α = 0.83).
• The General Psychopathology Subscale exhibited good internal consistency (α = 0.79).

The scale also exhibits good test-retest reliability, with reported Pearson correlation coefficients of 0.80, 0.68, and 0.60 for the positive, negative, and psychopathology subscales, respectively. Inter-rater reliability is similarly strong for the core syndromes, with Interclass Correlation Coefficients (ICCs) of 0.72 for the positive scale and 0.80 for the negative scale. Inter-rater reliability was found to be moderate (0.56) for the general psychopathology scale.

Factor Analysis

The original development of the PANSS was based on a dual-component model of independent positive and negative syndromes. Early factor analysis studies, however, indicated that this structure was overly simplistic. Specifically, early findings noted poor factorial validity for the positive scale, suggesting that the instrument struggled to definitively separate symptoms into only two or three distinct, non-overlapping factors.

While the scale was initially developed on the basis of independent components, clinical and statistical refinement has led to the acceptance of more complex factor structures, often involving five or more factors (e.g., excitement/hostility, cognitive impairment, and anxiety/depression). These findings underscore the scale’s complexity and have driven the creation of specialized administration formats, such as the PANSS-SCI (Structured Clinical Interview), to standardize data collection and improve factor structure consistency.

Instrument

Test Type: Clinical Rating Scale; Symptom Severity Assessment.

Format: Clinician-administered interview and observation. Each item is rated on a 7-point ordinal scale (1=absent to 7=extreme).

Language Available: Officially published across more than 40 languages, following sanctioned guidelines under the Multi Health Systems (MHS) Translation Policy (Khan et al., 2013).

Population Group: Individuals presenting with psychosis, primarily those diagnosed with schizophrenia.

Age Group: Typically utilized with adults.

Population Details: Originally validated among DSM-III-R schizophrenic patients. Alternate versions, such as the IQ-PANSS, are designed to acquire information from external informants like family members or case workers (MHS, 2006).

Test Methodology: Requires a trained clinician to conduct a structured interview and observe the patient’s behavior and presentation, typically focusing on the past week of symptoms. The PANSS-SCI version includes a structured interview guide to improve the reliability of scoring.

Keywords

Symptom measurement, clinical trial outcome, psychopharmacology, inter-rater reliability, internal consistency, MultiHealth Systems, PANSS-SCI, IQ-PANSS.

Authors

Author ORCID Identifier: N/A (Information not available in source content).

Affiliation Email addresses: N/A (Information not available in source content).

Correspondence Address: MultiHealth Systems (MHS), Inc., Toronto, Ontario, Canada.

Permissions & Fee and Test Year

The PANSS is a proprietary instrument managed by MultiHealth Systems (MHS), Inc. The use of the scale, including its manual, training materials, and scoring sheets, requires commercial permission and typically involves associated fees. The most widely referenced manual update was published in 2006 (Kay, Opler, & Fiszbein).

The original PDF concerning cross-cultural validity testing can be referenced here: http://A rasch model to test the cross-cultural validity in the positive and negative syndrome scale (PANSS) across six geo-cultural groups.

Reference’s

Canadian Agency for Drugs and Technologies in Health. (2011) A systematic review of combination and high dose atypical antipsychotic therapy in patients with schizophrenia. Ottawa: CADTH

Cuesta, M. J., & Peralta, V. (1995). Psychopathological dimensions in schizophrenia. Schizophrenia Bulletin, 21(3), 473-482.

Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS; 2006) manual. Toronto, Ontario: MultiHealth Systems, Inc.

Khan, A., Christian Yavorsky, C., Liechti, S., Opler, M., Rothman, B., Diclemente, G., Lucic, L., Jovic, S., Inada, T. and Yang, L. (2013). Available at: http://A rasch model to test the cross-cultural validity in the positive and negative syndrome scale (PANSS) across six geo-cultural groups [Accessed 17 Sep. 2017].

Kumari S, Malik M, Florival C, Manalai P, Sonje S (2017) An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS). J Addict Res Ther 8: 324. doi: 10.4172/2155-6105.1000324

Maust, D., Cristancho, M., Gray, L., Rushing, S., Tjoa, C. and Thase, M. (2012). Psychiatric rating scales. [online] Experts.umich.edu. Available at: https://experts.umich.edu/en/publications/psychiatric-rating-scales [Accessed 17 Sep. 2017].

Opler, L. A., Opler, M. G. and Malaspina, D. 2006. Reducing guesswork in schizophrenia treatment: PANSS can target and gauge therapy, predict outcomes in clinical practice. Current Psychiatry, 5: 76–84.

Taylor, Grantley W; McCarley, Robert W; Salisbury, Dean F (2013) Early auditory gamma band response abnormalities in first hospitalized schizophrenia. Suppl Clin Neurophysiol 62:131-45

Items of the Positive and Negative Syndrome Scale (PANSS)

IMPORTANT: The following scale items must be preserved in their original language and must not be changed in any way.

The PANSS is comprised of 30 items divided into three main subscales:

• Positive Syndrome: Pertaining to productive symptoms (7 items).
• Negative Syndrome: Pertaining to deficit features (7 items).
• General Psychopathology: Pertaining to general symptoms (16 items).

The scale was seemingly developed on the basis of independent components, intended to cover the core positive and negative syndromes of schizophrenia.